State of the Art: Treatment Update in Prostate Cancer- Oliver Sartor

Oliver Sartor and Charles Ryan discuss radioligand therapy, differentiating radioisotopes by properties and clinical application. They move to review the PSMA targeted agents and the clinical use of these agents in the treatment of prostate cancer.


A. Oliver Sartor, MD, Professor of Medicine, Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Research, Tulane University

Charles J. Ryan, MD


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.